$112 Million is the total value of Abingworth LLP's 14 reported holdings in Q1 2019. The portfolio turnover from Q4 2018 to Q1 2019 was 50.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| CRSP | Crisprnamen akt | $41,826,000 | +25.0% | 1,171,268 | 0.0% | 37.43% | +23.1% | |
| SIEN | Buy | Sientra | $20,466,000 | -26.8% | 2,390,843 | +8.7% | 18.32% | -27.9% |
| CHMA | Chiasma | $10,694,000 | +75.4% | 2,080,595 | 0.0% | 9.57% | +72.8% | |
| SLNO | Soleno | $9,619,000 | +20.5% | 4,669,272 | 0.0% | 8.61% | +18.7% | |
| AVDR | New | Avedro | $8,734,000 | – | 719,402 | +100.0% | 7.82% | – |
| PRTK | Paratek | $5,591,000 | +4.7% | 1,041,131 | 0.0% | 5.00% | +3.1% | |
| VRNA | Veronasponds adr | $5,502,000 | -32.2% | 901,943 | 0.0% | 4.92% | -33.2% | |
| SRRA | Sell | Sierra Oncology | $2,307,000 | +21.9% | 1,365,027 | -5.5% | 2.06% | +20.1% |
| AGLE | New | Aeglea | $1,934,000 | – | 240,500 | +100.0% | 1.73% | – |
| CBAY | Cymabay | $1,739,000 | +68.8% | 131,036 | 0.0% | 1.56% | +66.2% | |
| OBSV | Sell | Obseva | $1,118,000 | -79.9% | 87,999 | -80.0% | 1.00% | -80.2% |
| PRTO | Proteon | $1,009,000 | -78.0% | 2,017,872 | 0.0% | 0.90% | -78.3% | |
| RLM | New | Realmadr | $988,000 | – | 255,371 | +100.0% | 0.88% | – |
| HSGX | Buy | Histogenics | $206,000 | +167.5% | 1,777,778 | +100.0% | 0.18% | +162.9% |
| IMDZ | Exit | Immune Design | $0 | – | -352,300 | -100.0% | -0.42% | – |
| ADAP | Exit | Adaptimmunesponds adr | $0 | – | -250,000 | -100.0% | -1.31% | – |
| RARE | Exit | Ultragenyx | $0 | – | -38,100 | -100.0% | -1.50% | – |
| CLLS | Exit | Cellectissponds adr | $0 | – | -100,000 | -100.0% | -1.51% | – |
| AUPH | Exit | Aurinia Pharma | $0 | – | -400,434 | -100.0% | -2.47% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2019-05-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| SIENTRA INC | 33 | Q4 2022 | 31.2% |
| PARATEK PHARMACEUTICALS INC | 33 | Q4 2022 | 24.9% |
| CYMABAY THERAPEUTICS INC | 30 | Q4 2022 | 8.6% |
| Ocugen | 24 | Q2 2022 | 1.5% |
| Proteon | 22 | Q3 2020 | 18.9% |
| OBSEVA SA | 22 | Q4 2022 | 5.1% |
| Chiasma | 19 | Q1 2020 | 24.6% |
| VERONA PHARMA PLC | 18 | Q4 2022 | 20.9% |
| Sierra Oncology | 18 | Q2 2022 | 23.1% |
| Crispr | 16 | Q3 2020 | 53.6% |
View Abingworth LLP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Verona Pharma plc | August 11, 2022 | 21,313,822 | 4.4% |
| Sierra Oncology, Inc.Sold out | July 11, 2022 | 0 | 0.0% |
| HilleVax, Inc. | May 13, 2022 | 1,838,486 | 5.5% |
| SOLENO THERAPEUTICS INC | April 08, 2022 | 18,368,373 | 15.3% |
| Vera Therapeutics, Inc. | April 07, 2022 | 2,970,156 | 11.1% |
| EXICURE, INC. | February 25, 2022 | 7,084,297 | 6.5% |
| Vaxcyte, Inc. | February 14, 2022 | 4,183,716 | 7.9% |
| Jasper Therapeutics, Inc. | October 04, 2021 | 5,628,558 | 15.4% |
| eFFECTOR Therapeutics, Inc. | September 03, 2021 | 4,822,114 | 11.9% |
| Reneo Pharmaceuticals, Inc. | April 20, 2021 | 1,858,226 | 7.7% |
View Abingworth LLP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-02-12 |
| 13F-NT | 2024-02-02 |
| 13F-NT | 2023-11-03 |
| 4 | 2023-10-02 |
| 13F-NT | 2023-08-04 |
| 4 | 2023-05-10 |
| 13F-NT | 2023-05-05 |
| 13F-HR | 2023-02-10 |
| 4 | 2023-01-31 |
| 13F-HR | 2022-11-10 |
View Abingworth LLP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.